Loading…
Haemonetics Corporation is projected to rise to $121.27 by 2027, a +43% move from its current price of $84.82. HAE is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $83.39 | $84.90 | $86.44 | +0.10% |
| Aug 2 | $82.85 | $84.98 | $87.17 | +0.19% |
| Aug 3 | $82.46 | $85.07 | $87.76 | +0.29% |
| Aug 4 | $82.14 | $85.15 | $88.27 | +0.39% |
| Aug 5 | $81.87 | $85.23 | $88.73 | +0.48% |
| Aug 6 | $81.63 | $85.31 | $89.16 | +0.58% |
| Aug 7 | $81.43 | $85.40 | $89.56 | +0.68% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $81.43 | $85.40 | $89.56 | +0.68% |
| Week 2 | $80.38 | $85.98 | $91.96 | +1.36% |
| Week 3 | $79.71 | $86.56 | $94.00 | +2.05% |
| Week 4 | $79.23 | $87.15 | $95.85 | +2.74% |
| Week 5 | $78.88 | $87.74 | $97.60 | +3.44% |
| Week 6 | $78.61 | $88.33 | $99.26 | +4.14% |
| Week 7 | $78.41 | $88.93 | $100.87 | +4.85% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Haemonetics Corporation is a medical technology company that provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments, and offers automated plasma collection systems, donor management software, and related disposables and solutions, such as NexSys PCS plasmapheresis equipment system and NexLynk DMS donor management system.
It also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications.
The company offers hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient’s overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors.
The company was founded in 1971 and is headquartered in Boston, Massachusetts.
Haemonetics Corporation trades in the healthcare sector with a current price of $85.42 and a market capitalization of $3.88B. It is ranked 1566 by size.
The 2026 forecast lists a min of $52.24, an average of $85.42, and a max of $123.97, with ROI 0 and sentiment NEUTRAL.
From 2027 onward the forecast shows a rising trajectory, with 2027 avg $122.24, 2028 avg $138.22, 2029 avg $166.27, 2030 avg $182.60, 2031 avg $203.80, 2032 avg $239.50, 2033 avg $288.11, 2034 avg $346.45, 2035 avg $376.80, 2040 avg $595.41, and 2050 avg $1,343.21. The implied ROI grows from 43.1% in 2027 to 1472.5% in 2050; sentiment bullish throughout.
A major floor 38.4% below — a decisive break under it would weaken the trend.
The nearest floor, 14.5% below — buyers have tended to step in here.
Price is pressing into resistance (0.7% away) — a breakout level to watch.
A major ceiling 10.6% above — clearing it would confirm fresh momentum.
Key HAE support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of HAE market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $82.29 | Buy | $82.79 | Buy |
| MA 10 | $80.10 | Buy | $80.85 | Buy |
| MA 20 | $77.87 | Buy | $78.68 | Buy |
| MA 50 | $73.95 | Buy | $74.05 | Buy |
| MA 100 | $66.11 | Buy | $70.17 | Buy |
| MA 200 | $67.45 | Buy | $68.03 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 72.87 | Sell |
| Stoch RSI (14) | 88.22 | Sell |
| CCI (20) | 198.06 | Buy |
| Williams %R (14) | -5.45 | Info |
| MACD (12,26,9) | 0.59 | Buy |
| ROC (12) | 13.99 | Buy |
| Bollinger %B (20,2) | 1.05 | Sell |
| Stochastic %K (14) | 94.55 | Sell |
| TRIX (15) | 0.39 | Buy |
| Awesome (5,34) | 5.48 | Buy |
| Ultimate (7,14,28) | 80.22 | Sell |
| Momentum (10) | 6.32 | Buy |
| Aroon Osc (25) | 96.00 | Buy |
| Hull MA (9) | 85.13 | Sell |
| ADX (14) | 27.40 | Buy |
| ATR (14) | 1.24 | Info |
The 30-day technical picture is BULLISH with RSI14 at 80. The near-term trend shows the SMA50 at $73.40 and the SMA200 at $67.27, implying a positive drift relative to the current price.
Support and resistance levels are defined as $72.53 and $85.42 respectively, with a 30-day price range of $75.62 to $96.50. These indicators suggest upside potential if the price can extend beyond the current resistance while preserving a base above the nearby support.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $52.24 | $84.82 | $122.87 | 0% | Neutral | |
| $99.43 | $121.27 | $154.55 | +43% | Bullish | |
| $110.19 | $136.95 | $179.33 | +61% | Bullish | |
| $130.27 | $164.43 | $219.95 | +94% | Bullish | |
| $141.27 | $180.72 | $246.13 | +113% | Bullish | |
| $155.60 | $201.51 | $278.81 | +138% | Bullish | |
| $180.40 | $236.27 | $331.57 | +179% | Bullish | |
| $214.89 | $284.42 | $404.34 | +235% | Bullish | |
| $255.70 | $341.81 | $491.75 | +303% | Bullish | |
| $275.29 | $371.48 | $540.42 | +338% | Bullish | |
| $416.17 | $585.79 | $893.16 | +591% | Bullish | |
| $874.58 | $1,320.36 | $2,158.23 | +14.6x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $52.24 | $84.82 | $98.79 | +0.00% |
| August 2026 | $75.67 | $88.24 | $104.85 | +4.03% |
| September 2026 | $78.99 | $92.64 | $111.12 | +4.99% |
| October 2026 | $80.11 | $94.37 | $114.04 | +1.87% |
| November 2026 | $81.33 | $96.18 | $116.92 | +1.91% |
| December 2026 | $84.71 | $100.52 | $122.87 | +4.52% |
Click any year to see its month-by-month HAE forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect HAE to range from $52.24 to $122.87 through 2026. The $84.82 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The HAE price prediction for 2027 points to an average of $121.27 (low $99.43, high $154.55) — a potential gain of +43% on today's $84.82. Momentum favours further upside here.
In 2028, HAE is projected to trade between $110.19 and $179.33, averaging $136.95 — a potential gain of +61% from today's $84.82. That is up +13% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Haemonetics Corporation's 2029 outlook centres on $164.43, within a $130.27 to $219.95 range. That is up +20% on the projected 2028 average. That marks a +94% change versus current levels. Momentum favours further upside here.
By 2030, HAE could reach as high as $246.13, with a base case around $180.72 and support toward $141.27 — roughly +113% from $84.82. Buyers look set to stay in control over this stretch.
Expect HAE to range from $155.60 to $278.81 through 2031. The $201.51 average target implies a +138% move from current prices. That is up +12% on the projected 2030 average. Momentum favours further upside here.
The HAE price prediction for 2032 points to an average of $236.27 (low $180.40, high $331.57) — a potential gain of +179% on today's $84.82. Buyers look set to stay in control over this stretch.
In 2033, HAE is projected to trade between $214.89 and $404.34, averaging $284.42 — a potential gain of +235% from today's $84.82. That is up +20% on the projected 2032 average. Momentum favours further upside here.
Haemonetics Corporation's 2034 outlook centres on $341.81, within a $255.70 to $491.75 range. That is up +20% on the projected 2033 average. That marks a +303% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, HAE could reach as high as $540.42, with a base case around $371.48 and support toward $275.29 — roughly +338% from $84.82. Momentum favours further upside here.
Expect HAE to range from $416.17 to $893.16 through 2040. The $585.79 average target implies a +591% move from current prices. That is up +58% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The HAE price prediction for 2050 points to an average of $1,320.36 (low $874.58, high $2,158.23) — a potential gain of +14.6x on today's $84.82. Momentum favours further upside here.
Investing $1,000 in HAE today (≈ 11.789672 HAE) could be worth
$15,566.64
+$14,566.64 (+1457%) by 2050 · US Dollar
Based on the average projected HAE price of $1,320.36 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in HAEwould be worth at today's price.
$1,000 invested in HAE on Jul 30, 2025 (≈ 13.182178 HAE) would be worth
$1,118.11
+$118.11 (+11.8%) today · 1.12× · US Dollar
Based on a HAE entry price of $75.86 vs. today's $84.82.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $77.4 | $1,095.87 | +9.6% |
| 1 month ago | $75 | $1,130.93 | +13.1% |
| 3 months ago | $59.26 | $1,431.32 | +43.1% |
| 6 months ago | $66.66 | $1,272.43 | +27.2% |
| 1 year ago | $75.86 | $1,118.11 | +11.8% |
| All time (5.0y) ago | $61.31 | $1,383.46 | +38.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our HAE forecast.
Our base-case forecast reaches $170.00 around 2030.
Implied market cap at $170.00: $7.73B
2030 forecast: avg $182.60, min $142.72, max $248.70; ROI 113.8%; sentiment BULLISH.
2040 forecast: avg $595.41, min $423.00, max $907.85; ROI 597%; sentiment BULLISH.
2050 forecast: avg $1,343.21, min $889.69, max $2,195.61; ROI 1472.5%; sentiment BULLISH.
These long-range projections indicate strong upside potential over time, but they are estimates and not guarantees. The path to higher prices depends on factors beyond the numbers provided and should be considered in the context of broader market and healthcare sector dynamics.
Tap a question to reveal the answer.
2030 avg $182.60; min $142.72; max $248.70; ROI 113.8%; sentiment BULLISH.
The forecast shows bullish sentiment from 2027 onward with rising averages (e.g., 2027 avg $122.24; 2040 avg $595.41; 2050 avg $1,343.21), but these are estimates and not guarantees.
Yes. The 2027 max is $155.80 and the 2028 max is $181.00, indicating forecasts where $150 is surpassed.
Current price is $85.42. The 30-day range is $75.62–$96.50, RSI(14) is 80, SMA50 is $73.40, SMA200 is $67.27, with support at $72.53 and resistance at $85.42.
Market cap is $3.88B and rank is 1566.
Haemonetics Corporation Community Discussion
0Share your Haemonetics Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.